Active, not recruitingNCT03636438
Long Term Follow Up to Evaluate DTX301 in Adults With Late-Onset OTC Deficiency
Studying Ornithine transcarbamylase deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ultragenyx Pharmaceutical Inc
- Principal Investigator
- Medical DirectorUltragenyx Pharmaceuticals Inc
- Intervention
- No Intervention(other)
- Enrollment
- 11 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2029
Study locations (9)
- The Children's Hospital Colorado, Aurora, Colorado, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- Icahn School of Medicine, New York, New York, United States
- University Hospital Cleveland Medical Center/Case Western Reserve University, Cleveland, Ohio, United States
- M.A.G.I.C. Clinic, Calgary, Alberta, Canada
- Hopital Femme Mere Enfant, Bron, Rhone, France
- Hospital Clinico Universitario de Santiago, Santiago de Compostela, Coruna, Spain
- Hospital Universitario de Cruces. Servicio de Pediatria, Barakaldo, Vizcaya, Spain
- Queen Elizabeth Hospital, Department of Endocrinology, Birmingham, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03636438 on ClinicalTrials.govOther trials for Ornithine transcarbamylase deficiency
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06805695Long-term Follow-up (LTFU) Study of Participants in Any iECURE Protocol Using an Investigational Product (IP)iECURE, Inc.
- RECRUITINGPHASE2NCT06488313A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCDArcturus Therapeutics, Inc.
- RECRUITINGPHASE1, PHASE2NCT06255782An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC DeficiencyiECURE, Inc.
- RECRUITINGPHASE1, PHASE2NCT05092685Halting Ornithine Transcarbamylase Deficiency With Recombinant AAV in ChildrEnUniversity College, London
- ACTIVE NOT RECRUITINGPHASE3NCT05345171Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) DeficiencyUltragenyx Pharmaceutical Inc
- RECRUITINGNCT04908319Hepatic Histopathology in Urea Cycle DisordersBaylor College of Medicine
- ACTIVE NOT RECRUITINGNCT04612764Liver Disease in Urea Cycle DisordersBaylor College of Medicine